Skip to main content
OpenTrials
Completed

NCT Number: NCT07508098

Comparison of Efficacy of Topical Westerhoff Formula Cream Vs Topical 4% Hydroquinone for the Treatment of Melasma

study was conducted on middle aged male and female, including families and health care professional also.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Melasma (Facial Melasma) Hyperpigmentation Melanosis Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases

Age range

15 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Dermatology Department of Tertiary Care Hospital

Rawalpindi, Punjab Province, 46000, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patient with facial melasma of age between 15 years to 45 years of both gender

Exclusion criteria

  • patient who have already taken treatment within 8 weeks, pregnant women, who are taking hormonals therapy and patient of dementia

Treatment and study plan

Triple combination cream

Drug

4.7% N-acetylcysteine, 2% Hydroquinone and 0.1 % triamcinolone acetate twice daily for 8 weeks

Hydroquinone 4% Cream

Drug

twice daily for 8 weeks

Primary outcomes

  1. proportion of participants achieving 60% reduction in the melasma area severity index (MASI-60)

    Time frame: 8 weeks

    the primary outcome is the proportion of the participants achieving 60% reduction in MASI score from baseline after 8 weeks of treatment. MASI is the scoring system used to assess the melasma on the basis of severity darkness and the homogeneityenicity

  2. proportion of participants achieving >60% reduction in Melasma Area and severity index (MASI-60)

    Time frame: baseline to 8 weeks

    The primary outcome is the proportion of the participants achieving 60% reduction in MASI Score rom the baseline after treatment. MASI is the scoring system used to assess the severity of melasma based on the area, darkness nd the homogeneity

Sponsors and collaborators

Lead sponsor

Pak Emirates Military Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 2, 2026
Registry last updated
Apr 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.